Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian
immuno-oncology company, will release its first quarter 2024 results on
Thursday, 30 May 2024. The results will be presented in a webcast with CEO
Øystein Rekdal and CFO Gjest Breistein at 1:00pm CET. 

We encourage you to send us questions in advance, to be addressed during the Q&A
session. Please send your questions in an email to post@lytixbiopharma.com. 

The presentation and subsequent Q&A session will be held in English and may be
viewed live by registering here: https://forms.office.com/e/0djcLzR8Za

A recording of the presentation will be made available on
https://www.lytixbiopharma.com/financial-reports after the presentation.

For more information, please contact: 
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com


About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.